Идёт набор NCT05283226

Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Фаза II С лечением Carcinoma Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: NRC-2694-A, Paclitaxel.
Кому может быть актуально: Состояния в реестре: Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: США, Индия
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

A Phase 2 Multicenter, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy

Обзор

This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy. A total of approximately 46 male and female patients will be enrolled. This sample size is based on Simon's 2-stage design with historical control ORR of 30% and a target ORR of 50%.

Подробное описание

Patients with recurrent and/or metastatic unresectable Head and Neck Cancer have a poor prognosis and limited treatment options. Pembrolizumab and Nivolumab, both ICIs (Immune Checkpoint Inhibitors), are approved therapies for this condition. However, no approved treatment options exist for patients who progress on ICI therapies. Hence, there is an unmet medical need post-failure of ICI therapy. NRC-2694-A is an orally administered small-molecule tyrosine kinase inhibitor. It was discovered and developed by NATCO Pharma Ltd. NRC-2694-A demonstrated response in HNSCC patients in a Phase-I study as a monotherapy. This was further substantiated in a Phase-II study in combination with cisplatin/carboplatin and paclitaxel.

Вмешательства

Препарат NRC-2694-A
300 mg orally once daily
Препарат Paclitaxel
175 mg/m² IV infusion over approximately 3 hours

Первичные конечные точки

To determine if NRC-2694-A administered orally in combination with paclitaxel demonstrates objective response in patients with R/M HNSCC, who have had radiological progression on or after treatment with ICI therapies like pembrolizumab or nivolumab [Срок оценки: Baseline through approximately up to 24 weeks]

Вторичные конечные точки (12)

Progression-free survival [Срок оценки: Baseline through approximately up to 24 weeks]
Overall survival [Срок оценки: Baseline through approximately up to 24 weeks]
Duration of response [Срок оценки: Baseline through approximately up to 24 weeks]
Clinical benefit response [Срок оценки: Baseline through approximately up to 26 weeks]
Number of adverse events [Срок оценки: Baseline through approximately up to 24 weeks]
Number of participants with abnormal physical examination findings [Срок оценки: Baseline through approximately up to 24 weeks]
Number of participants with abnormal vital signs [Срок оценки: Baseline through approximately up to 24 weeks]
Assessing safety through ECOG (Eastern Cooperative Oncology Group) [Срок оценки: Baseline through approximately up to 24 weeks]
Number of participants with abnormal clinical laboratory tests results [Срок оценки: Baseline through approximately up to 24 weeks]
Number of participants with abnormal ECGs (Electrocardiograms) [Срок оценки: Baseline through approximately up to 24 weeks]
Plasma PK parameters of NRC-2694-A measured via Cmax (Maximum plasma concentration) [Срок оценки: Baseline through approximately up to 24 weeks]
Plasma PK parameters of NRC-2694-A measured via Tmax (time to reach the maximum plasma concentration) [Срок оценки: Baseline through approximately up to 24 weeks]

Критерии участия

Критерии включения

Is willing and capable of understanding the written informed consent, provides signed and witnessed written informed consent, and agrees to comply with protocol requirements.
Is male or female aged 18 years or older at the time of consent.
Has histologically confirmed unresectable R/M HNSCC (oral cavity, oropharynx, hypopharynx, and larynx).
Has documented progressive disease assessed by the principal investigator according to RECIST v1.1.
Has a measurable lesion per RECIST v1.1.
Has ECOG performance status score of ≤2.
Must have progressed during or after receiving ICI therapy, such as pembrolizumab or nivolumab. Patients with prior immune-mediated reactions due to ICI therapies (eg, pembrolizumab or nivolumab) and who had recovered prior to study entry will also be eligible.
Female patients of childbearing potential should have a negative urine test before enrollment. If the urine pregnancy test is positive or gives equivocal results, a serum pregnancy will be required for confirmation.
Patients of reproductive age must use acceptable methods of contraception throughout the study period and for 30 days following the last dose of investigational product (see protocol for further guidance).
During screening and at subsequent visits, the investigator should ensure adequate bone marrow reserve (neutrophil count ≥1500/mm3, platelet count ≥100,000/mm3, and hemoglobin level 8.0 g/dL), renal function (creatinine clearance ≥30 mL/min calculated by Cockcroft-Gault formula), liver function (total bilirubin level ≤1.5 × ULN \[except patients with documented Gilbert's syndrome\] and serum transaminase levels ≤2.5 × ULN or ≤5 × ULN for liver metastasis and/or obstructive jaundice).
Must have completed a duration of at least two weeks after stopping ICI therapy/investigational therapy/salvage therapy and must have recovered to grade ≤1 from all toxicities due to such therapies.

Критерии исключения

Has cardiac, hepatic, endocrine, pulmonary, or autoimmune disease, interstitial lung disease, renal or psychiatric disorders, not controlled with therapy corresponding to the illness or a condition that contraindicates the use of a taxane or an EGFR inhibitor.
Has Cirrhosis of liver at a level of Child-Pugh B (or worse).
Has uncontrolled brain metastases. Patients are allowed if brain metastasis has been previously treated with surgery, whole brain irradiation, and/or stereotactic radiosurgery and are considered controlled (controlled by the dose ≤10 mg/day of prednisone or equivalent) at the time of the first dose of investigational product. Radiological evaluation of brain metastasis will be performed only if the patient has symptoms. For asymptomatic patients, brain imaging during screening is not required.
Has baseline prolongation of QT/QTc interval (eg, repeated demonstration of a QTc interval >480 milliseconds \[CTCAE Grade 1\] using Fredericia's QT correction formula).
Has a history of additional risk factors for Torsade de pointes (eg, heart failure, hypokalemia, family history of long QT syndrome).
Has had prior cetuximab therapy for recurrent or metastatic disease. Note that cetuximab used concomitantly with radiotherapy or as an induction therapy is acceptable
Has received any other EGFR-targeted therapies for recurrent or metastatic disease.
Currently participating in any clinical trial or receiving investigational therapy on expanded access or compassionate basis.
Has nasopharyngeal carcinomas or salivary gland cancers.
Female patient who tested positive for pregnancy.
Female patient who is breastfeeding or planning to become pregnant, or male patient planning to father a child within the duration of the study.
Has tested positive for HIV, HBsAg, HCV antibody, or HCV RNA at screening. However, patients who test positive for HCV antibody, but negative for HCV RNA, will be allowed. In addition, patients with controlled HIV, chronic HBV on suppressive antiviral therapy, or a history of HCV infection status post-curative antiviral treatment with an HCV viral load below limit of quantification are permitted to participate (DHHS 2020).
Has active infection requiring intravenous anti-infective therapy within 7 days prior to Day 1 Cycle 1 or is febrile due to infection.
Has had major surgery within 4 weeks prior to screening.
Administered a live attenuated vaccine within 4 weeks prior to Day 1 Cycle 1 or anticipation that such a live attenuated vaccine will be required during the study.
Has known or suspected hypersensitivity to any components of the formulation used for this investigational product.
Has concurrent disease or any clinically significant abnormality following the investigator's review of the screening physical examination findings, 12-lead ECG results, and clinical laboratory tests, which in the judgment of the investigator would interfere with the patient's participation in this study or evaluation of study results.
Unable to come for study visits per schedule.
Has current drug or alcohol abuse.
Has received prior treatment with paclitaxel or docetaxel or any other drugs with taxane like mode of action for recurrent or metastatic or recurrent HNSCC. However, prior paclitaxel or docetaxel or any other drugs with taxane like mode of action as a component of a curatively-intended multimodality treatment for locally advanced HNSCC is permitted.